Display options
Cite
Rodriguez H, Zenklusen JC, Staudt LM, et al. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell. 2021;184(7):1661-1670doi: 10.1016/j.cell.2021.02.055.
Rodriguez, H., Zenklusen, J. C., Staudt, L. M., Doroshow, J. H., & Lowy, D. R. (2021). The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell, 184(7), 1661-1670. https://doi.org/10.1016/j.cell.2021.02.055
Rodriguez, Henry, et al. "The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment." Cell vol. 184,7 (2021): 1661-1670. doi: https://doi.org/10.1016/j.cell.2021.02.055
Rodriguez H, Zenklusen JC, Staudt LM, Doroshow JH, Lowy DR. The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment. Cell. 2021 Apr 01;184(7):1661-1670. doi: 10.1016/j.cell.2021.02.055. PMID: 33798439; PMCID: PMC8459793.
Copy Download .nbib Format: NLM
Share it on

Cell. 2021 Apr 01;184(7):1661-1670. doi: 10.1016/j.cell.2021.02.055.

The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.

Cell

Henry Rodriguez, Jean Claude Zenklusen, Louis M Staudt, James H Doroshow, Douglas R Lowy

Affiliations

  1. Office of Cancer Clinical Proteomics Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Electronic address: [email protected].
  2. Center for Cancer Genomics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  3. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  4. Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

PMID: 33798439 PMCID: PMC8459793 DOI: 10.1016/j.cell.2021.02.055

Abstract

When it comes to precision oncology, proteogenomics may provide better prospects to the clinical characterization of tumors, help make a more accurate diagnosis of cancer, and improve treatment for patients with cancer. This perspective describes the significant contributions of The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium to precision oncology and makes the case that proteogenomics needs to be fully integrated into clinical trials and patient care in order for precision oncology to deliver the right cancer treatment to the right patient at the right dose and at the right time.

Published by Elsevier Inc.

Keywords: cancer diagnosis; cancer treatment; clinical trial; collaboration; data sharing; genomics; molecular medicine; open access; precision medicine; precision oncology; proteogenomics; proteomics; targeted therapy

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

  1. Nat Rev Clin Oncol. 2019 Apr;16(4):256-268 - PubMed
  2. Nature. 2016 May 25;534(7605):55-62 - PubMed
  3. Mol Cell Proteomics. 2014 Mar;13(3):907-17 - PubMed
  4. Mol Syst Biol. 2008;4:222 - PubMed
  5. Surg Oncol Clin N Am. 2020 Jan;29(1):35-49 - PubMed
  6. Nature. 2001 Feb 15;409(6822):860-921 - PubMed
  7. J Adolesc Health. 2019 Dec;65(6):715-722 - PubMed
  8. Nature. 2013 May 2;497(7447):67-73 - PubMed
  9. Nat Methods. 2014 Feb;11(2):149-55 - PubMed
  10. Clin Pharmacol Ther. 2017 May;101(5):619-621 - PubMed
  11. Cell Rep Med. 2020 Aug 25;1(5): - PubMed
  12. J Natl Cancer Inst. 2020 Oct 1;112(10):1021-1029 - PubMed
  13. Mol Cell Proteomics. 2020 May;19(5):828-838 - PubMed
  14. N Engl J Med. 2015 Feb 26;372(9):793-5 - PubMed
  15. N Engl J Med. 2016 Sep 22;375(12):1109-12 - PubMed
  16. Lancet Oncol. 2015 Oct;16(13):1324-34 - PubMed
  17. Mol Cell Proteomics. 2010 Feb;9(2):242-54 - PubMed
  18. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  19. Nat Methods. 2013 Jan;10(1):24-7 - PubMed
  20. N Engl J Med. 2020 Aug 13;383(7):640-649 - PubMed
  21. Cell. 2020 Dec 23;183(7):1962-1985.e31 - PubMed
  22. Cell. 2018 Apr 19;173(3):535-539 - PubMed
  23. Clin Chem. 2010 Feb;56(2):165-71 - PubMed
  24. Nat Commun. 2020 Apr 9;11(1):1759 - PubMed
  25. Clin Chem. 2013 Jun;59(6):982-90 - PubMed
  26. Br J Cancer. 2018 Nov;119(10):1233-1243 - PubMed
  27. Nat Rev Clin Oncol. 2017 May;14(5):317-323 - PubMed
  28. Bioinformatics. 2008 Dec 15;24(24):2894-900 - PubMed
  29. Nat Biotechnol. 2009 Jul;27(7):633-41 - PubMed
  30. Genome Biol. 2018 Oct 22;19(1):161 - PubMed
  31. Cell. 2016 Jul 28;166(3):755-765 - PubMed
  32. Curr Mol Med. 2007 Feb;7(1):133-41 - PubMed
  33. Clin Chem. 2010 Feb;56(2):237-43 - PubMed
  34. Anal Chem. 2017 Jul 18;89(14):7406-7415 - PubMed
  35. Int J Pharm. 2005 Aug 11;299(1-2):1-18 - PubMed
  36. Nature. 2014 Sep 11;513(7517):202-9 - PubMed
  37. Nat Med. 2019 May;25(5):751-758 - PubMed
  38. Mol Cell Proteomics. 2014 Jul;13(7):1690-704 - PubMed
  39. J Oncol Pract. 2018 Oct 4;:JOP1800092 - PubMed
  40. Clin Chem. 2014 Jul;60(7):1016-8 - PubMed
  41. Sci Transl Med. 2010 Sep 15;2(49):49cm24 - PubMed
  42. Cancer Cell. 2021 Mar 8;39(3):361-379.e16 - PubMed
  43. Cell. 2019 Oct 3;179(2):561-577.e22 - PubMed
  44. Crit Rev Oncol Hematol. 2013 Jul;87(1):55-68 - PubMed
  45. N Engl J Med. 2015 Aug 20;373(8):726-36 - PubMed
  46. J Investig Med. 2012 Dec;60(8):1157-63 - PubMed
  47. J Proteome Res. 2010 Feb 5;9(2):761-76 - PubMed
  48. Nat Commun. 2020 Jan 27;11(1):532 - PubMed
  49. Cell. 2018 Apr 5;173(2):530 - PubMed
  50. Cell. 2019 Oct 31;179(4):964-983.e31 - PubMed
  51. Cell. 2020 Feb 20;180(4):729-748.e26 - PubMed
  52. Nat Commun. 2017 Sep 6;8(1):465 - PubMed
  53. Nat Rev Clin Oncol. 2018 Mar;15(3):183-192 - PubMed
  54. Acta Neuropathol. 2017 Jan;133(1):1-3 - PubMed
  55. Nat Methods. 2013 Jan;10(1):28-34 - PubMed
  56. Bioessays. 2007 Aug;29(8):783-94 - PubMed
  57. Science. 2001 Feb 16;291(5507):1304-51 - PubMed
  58. Nature. 2013 Sep 19;501(7467):355-64 - PubMed
  59. Cell. 2017 Feb 9;168(4):584-599 - PubMed
  60. Nature. 2007 Aug 2;448(7153):561-6 - PubMed
  61. Clin Chem. 2008 Nov;54(11):1796-804 - PubMed
  62. Cell. 2020 Jul 9;182(1):226-244.e17 - PubMed
  63. J Clin Endocrinol Metab. 2013 Apr;98(4):1343-52 - PubMed
  64. CA Cancer J Clin. 2020 Sep;70(5):321-346 - PubMed
  65. Cancer Cell. 2019 Jan 14;35(1):111-124.e10 - PubMed
  66. Nature. 2014 Sep 18;513(7518):382-7 - PubMed
  67. Cell. 2019 May 2;177(4):1035-1049.e19 - PubMed
  68. Cancer Biol Ther. 2009 Jun;8(12):1083-94 - PubMed
  69. N Engl J Med. 2015 Jun 25;372(26):2481-98 - PubMed
  70. Nat Methods. 2014 Jul;11(7):703-4 - PubMed
  71. Cell. 2020 Jul 9;182(1):200-225.e35 - PubMed
  72. J Proteome Res. 2009 Feb;8(2):787-97 - PubMed
  73. Science. 2008 Nov 21;322(5905):1259-62 - PubMed

MeSH terms

Publication Types

Grant support